AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer
By The Cancer News Team
WU-KONG28 and LIBRETTO-432 delivered practice-changing data at ASCO 2026 for molecularly defined NSCLC. A thoracic oncologist breaks down what sunvozertinib and selpercatinib mean for frontline and adjuvant care.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
What Every Oncologist Needs to Know About CAR-T Toxicity
By John Mathews, MD
CAR-T toxicity doesn't end at the cancer center — it follows patients home. A community oncologist's guide to recognizing and managing CRS, IEC-HS, ICANS, late infections, and delayed neurotoxicity.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab
By Lee Cranmer, MD/PhD/FACP
The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and Changes in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and Changes in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and Changes in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
ASCENT-03, ASCENT-04, and Dato-DXd: How ADCs Are Replacing Chemotherapy in Metastatic TNBC
By Vijayakrishna Gadi, PhD, MD
ADCs are now first-line options in metastatic TNBC regardless of PD-L1 status. Dr. VK Gadi breaks down ASCENT-03, ASCENT-04, and Dato-DXd—and what's coming next in a rapidly shifting treatment landscape.
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
Prostate Cancer in 2026: Personalizing ADT Duration, Earlier PARP Inhibitors, and a New Bispecific
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Prostate Cancer in 2026: Personalizing ADT Duration, Earlier PARP Inhibitors, and a New Bispecific
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Prostate Cancer in 2026: Personalizing ADT Duration, Earlier PARP Inhibitors, and a New Bispecific
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move Up, Immunotherapy Stays Central, Biomarkers Lag
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move Up, Immunotherapy Stays Central, Biomarkers Lag
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move Up, Immunotherapy Stays Central, Biomarkers Lag
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.